Clinical Trial Update: Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of lenvatinib and pembrolizumab for well-differentiated neuroendocrine tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Neuroendocrine Carcinoma
• Neuroendocrine Carcinoma
• Neuroendocrine Tumor

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: University of California, San Francisco | Conditions: Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma | Phase 2 | Status: RECRUITING